American Portfolios Advisors’s Nektar Therapeutics NKTR Stock Holding History

American Portfolios Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$736	Hold	15	–	–	﹤0.01%	3330
2022 Q2	$874	Hold	15	–	–	﹤0.01%	3298
2022 Q1	$1.24K	Sell	15 -17	-53%	-$2.52K	﹤0.01%	3323
2021 Q4	$6.49K	Hold	32	–	–	﹤0.01%	2798
2021 Q3	$8.62K	Buy	32 +13	+68%	+$3.13K	﹤0.01%	2631
2021 Q2	$4.8K	Sell	19 -3	-14%	-$830	﹤0.01%	2828
2021 Q1	$6.7K	Hold	22	–	–	﹤0.01%	2574
2020 Q4	$5.7K	Hold	22	–	–	﹤0.01%	2356
2020 Q3	$5.56K	Sell	22 -27	-55%	-$8.49K	﹤0.01%	2232
2020 Q2	$17K	Hold	49	–	–	﹤0.01%	1708
2020 Q1	$13.1K	Hold	49	–	–	﹤0.01%	1704
2019 Q4	$15.9K	Hold	49	–	–	﹤0.01%	1819
2019 Q3	$13.4K	Buy	49 +13	+36%	+$4.77K	﹤0.01%	1821
2019 Q2	$19K	Buy	36 +4	+13%	+$2.01K	﹤0.01%	1681
2019 Q1	$16.1K	Sell	32 -3	-9%	-$1.78K	﹤0.01%	1655
2018 Q4	$17.3K	Hold	35	–	–	﹤0.01%	1430
2018 Q3	$32K	Sell	35 -4	-10%	-$3.41K	﹤0.01%	1296
2018 Q2	$28.6K	Buy	+39	New	+$45K	﹤0.01%	1310

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

American Portfolios Advisors's NKTR Position: Q3 2022 in Review

American Portfolios Advisors held its Nektar Therapeutics (NKTR) position steady in Q3 2022 at 15 shares worth $736. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

American Portfolios Advisors first reported a position in NKTR in Q2 2018 and has held it in 18 quarters since. The position peaked at $32K in Q3 2018. 231 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

American Portfolios Advisors held 15 shares of Nektar Therapeutics worth $736 as of Q3 2022.
American Portfolios Advisors left its Nektar Therapeutics share count unchanged in Q3 2022.
Nektar Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3330 holding.
American Portfolios Advisors first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 18 quarters since.
American Portfolios Advisors's Nektar Therapeutics position peaked at $32K in Q3 2018.
231 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.